Shan Li

Shan Li

Auto-generated profile, based on publicly available information

Shan Li

The First Affiliated Hospital of Xian Jiaotong University

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2023 in The FASEB Journal
Verified
Journal Article
Open access
QFQian Feng
Qian Feng
NCNan Cui
Nan Cui
SLShan Li
Shan Li
JCJing Cao
Jing Cao
QCQian Chen
Qian Chen
HWHaiyan Wang
Haiyan Wang
Sry‐box9 (SOX9) maintains stem cell properties and plays crucial roles in many cancers. However, whether SOX9 is correlated with cervical cancer cell stemness and its detailed mechanism remains obscure. We studied the relationship between SOX9 and prognosis of cervical cancer through public database, and SOX9 was related to poor prognosis of cervical cancer. Elevated SOX9 expression enhanced the self‐renewal properties and promotes tumorigenicity in cervical cancer. Overexpression of SOX9 could promote the expression of stem cell‐related factors in cervical cancer cells and xenografts. Meanwhile, overexpression of SOX9 could also enhance the expressions of FZD10, β‐catenin, and c‐Myc in cervical cancer cells and xenografts, while inhibiting the expression of DDK1. The activation of Wnt pathway by chir‐99 021 raised the tumor spheroid ability of SOX9 knockdown HeLa cells. In addition, SOX9 could transcriptional inhibit DKK1 and activate FZD10 and MYC by binding to their promoters to affect the Wnt/β‐catenin pathway. These results demonstrated SOX9 regulated the self‐renewal and tumorigenicity of cervical cancer through Wnt/β‐catenin pathway by directly transcriptional activation of FZD10, MYC and transcriptional inhibition of DKK1.

8 June 2014 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
BRBrian I. Rini
Brian I. Rini
BRB. Redman
B. Redman
JGJ. A. Garcia
J. A. Garcia
HBH. A. Burris
H. A. Burris
SLS. Li
S. Li
JIJ. R. Infante
J. R. Infante
This phase I/II study was conducted to determine the maximum tolerated dose (MTD), safety, and efficacy of lenalidomide plus sunitinib in metastatic renal cell carcinoma (RCC) patients. Patients with histologically confirmed, metastatic RCC were treated with 10 mg/day lenalidomide plus 37.5 mg/day sunitinib, orally in 21-day cycles. Doses were escalated to determine the MTD in phase I, with additional patients planned at this dose in phase II. Primary end points were MTD and response rate. Sixteen patients received a median of 2, 3, and 5 cycles in cohort 1 [lenalidomide 10 mg (days 1–21) and sunitinib 37.5 mg (days 1–21)], cohort 2 [lenalidomide 10 mg (days 1–21) and sunitinib 37.5 mg (days 1–14)], and cohort 3 [lenalidomide 15 mg (days 1–21) and sunitinib 37.5 mg (days 1–14)], respectively. Median treatment durations were 41, 63, and 97 days for lenalidomide; and 41, 57, and 97.5 days for sunitinib. The MTD was found to be continuous dosing of lenalidomide 10 mg/day plus sunitinib 37.5 mg/day for 14 of 21 days. Dose-limiting toxicities included neutropenia, leukopenia, thrombocytopenia, asthenia, atrial fibrillation, and increased transaminases. The most frequent grade 3–4 treatment-emergent adverse events were hematologic, including neutropenia and leukopenia. One patient achieved partial response, and seven had stable disease of which three were confirmed at subsequent tumor assessments. B cells and several T-cell subsets were modulated versus baseline. The dose schedules of lenalidomide and sunitinib evaluated in this study were not well tolerated; cumulative toxicity precluded enrollment at the MTD.

14 July 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
WYWenting Yang
Wenting Yang
XZXiaorui Zhang
Xiaorui Zhang
RXRui Xu
Rui Xu
ZHZhuoqi Huang
Zhuoqi Huang
YMYanmin Ma
Yanmin Ma
GTGuoqing Tong
Guoqing Tong
Ovarian aging is closely associated with a decline in fertility and an increase in reproductive dysfunction. Ovarian granulosa cells (GCs) support oocyte homeostasis and development, yet insight into GC dysfunction during aging is limited. Here, we show that aged GCs of humans and mice have indications of elevated ferroptosis, including increased ferroptosis-related metabolites, lipid peroxidation, and iron accumulation. The ferroptosis inhibitor Ferrostatin-1 reversed ovarian impairment and fertility of aged mice in vivo . We show that the age-related reduction in the expression of TXN (thioredoxin) leads to ferroptosis in human and mouse GCs by blocking BNIP3L-dependent mitophagy. Exogenous activation of TXN could promote mitophagy, thereby clearing excessive ROS and inhibiting ferroptosis. These results suggest that anti-ferroptosis-related treatments may assist in treating aging-related reproductive disorders. Abstract Figure: Key points: Ferroptosis signatures are upregulated in aged GCs from human and mouse ovaries TXN is deregulated in aged GCs, leading to mitochondrial and ROS metabolic dysfunction TXN binds to DNA to regulate autophagy and mitophagy genes, including BNIP3L Inhibition of ferroptosis can ameliorate GC dysfunction